Cargando…
Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
BACKGROUND: Early non-response to antipsychotic treatment in patients with schizophrenia has been shown in multiple studies to predict poor response at short-term trial endpoint. Therefore, strategies to address the challenge of non-improvement early in the course of treatment are needed. A novel tr...
Autores principales: | Loebel, Antony, Citrome, Leslie, Correll, Christoph U., Xu, Jane, Cucchiaro, Josephine, Kane, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628370/ https://www.ncbi.nlm.nih.gov/pubmed/26521019 http://dx.doi.org/10.1186/s12888-015-0629-0 |
Ejemplares similares
-
Effectiveness of lurasidone in schizophrenia or schizoaffective patients
switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013) -
Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015) -
Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Goldman, Robert, et al.
Publicado: (2017) -
PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies
por: Potkin, Steven G., et al.
Publicado: (2016) -
F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
por: Goldman, Robert, et al.
Publicado: (2018)